Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

Item

http://www.wikidata.org/entity/Q34691516

Q34691516

about

Phase I trial of temozolomide (CCRG 81045: M&B; 39831: NSC 362856)Contemporary murine models in preclinical astrocytoma drug development Fasting enhances the response of glioma to chemo- and radiotherapy Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.Chemotherapeutic Drugs Interfere with Gene Delivery Mediated by Chitosan-Graft-Poly(ethylenimine)Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.Temozolomide in paediatric high-grade glioma: a key for combination therapy?Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group Evaluation of the exposure equivalence of oral versus intravenous temozolomide.A peptide & peptide nucleic acid synthesis technology for transporter molecules and theranostics--the SPPS.Progress in the treatment of neuroendocrine tumors.Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs The medicinal chemistry of imidazotetrazine prodrugs Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53.Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.α-Carboline derivative TJY-16 inhibits tumor growth by inducing G2/M cell cycle arrest in glioma cells.Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents Direct detection and quantification of abasic sites for in vivo studies of DNA damage and repair.Temozolomide and cisplatin in relapsed/refractory acute leukemia.

P2860

Q24683819-99B83C61-819F-418E-AD25-199DB62F7D29 Q27026937-EC9C822A-FD07-458D-99F1-FA70ABDC14A4 Q27320014-8BB67AFC-3832-4808-A59E-A69181D794E6 Q27322329-DFC393A7-B73E-4C74-91A1-E00E33C84B1A Q28547144-E3395036-CCF4-4756-A853-BCE8C8B28553 Q33330748-72498CB6-17FF-4852-8C14-86EEC43F2C22 Q33346715-F2F25790-07FC-4B4E-A4E7-C142822F8B21 Q33347264-65844C5A-9266-4A38-B277-D2EFCCA90E4C Q33349020-7A8A2785-9418-4672-AA9B-93865A3BAA10 Q33357549-74185622-00C2-479A-B3F5-F1E6004AF900 Q33361765-8FB3C59F-9A94-496B-B913-D4E3D0CB1BA7 Q33377664-661673BB-058B-460B-B305-79EC37D923DF Q33379701-99B6C305-73A5-4D50-80E2-6D677FABCB36 Q33413067-779F73F5-EDAF-42FB-827B-D76244A6A22F Q33430404-9C6E319D-404A-4319-A6B9-4E50F55B1DC5 Q33503725-E0BEB183-D3ED-4F56-8365-EFE9F495E6C0 Q33599155-274EEEB0-2868-4BC4-88CB-92E3E8EE553B Q33628437-009172C8-878B-4B94-BAD1-602C796DABCB Q33643643-BCB3ABFD-6234-4FC2-9089-4D0E82C55204 Q33948026-9F15FEDD-3C97-416B-B28E-8B0F7D348320 Q33963114-0E99A462-CB0D-4143-81D5-4CB015C440DE Q34000287-CB7884FE-8C59-412F-8FDF-FEED08E2C025 Q34178990-9F550DA0-A9DE-4C6E-80BC-213DF3772F80 Q34344177-2120B75D-2ECE-4681-A553-237684CB111A Q34447471-F6A4F0C9-58BA-441A-A36B-8771ADDAAD05 Q34571940-070EA43F-AF63-4085-984E-36FC09E8F1EB Q35001754-375DCDBA-0BF0-4939-90FD-2767DD24CFB9 Q35020652-BA34CB55-A5B9-4AEF-8779-B4EEF341BAD2 Q35440540-12A1D6B4-659B-48E3-BDE3-B3FCF9242FE5 Q35898306-1870AD12-C35C-42E5-B535-D3C4ED5E8578 Q35978302-60D1E82F-4415-47EA-BFC8-B9D5804A423A Q36081960-564EE8BB-4CD7-4244-BC03-E265666BEDEA Q36431155-CFCE3FE0-74BD-443E-B028-EAB0C6FA8FFC Q36455403-220F2946-2007-4D63-9539-BAECF087C5BE Q36621800-B8CD03B5-F0B8-424C-AF0A-AD4EC7E49214 Q36866006-672EA373-DA3B-45E8-AC4E-EA008D5B81E9 Q37020085-C4C48DD6-1438-44DE-8DFD-0F46BF566B25 Q37056618-2213901A-1830-4682-8B51-C61C7D99BCB3 Q37188627-2A89595E-F742-465A-974A-6A32BBD092E6 Q37223615-6ECFBFB6-8323-4A65-924D-3A8C24CC4DA8

P2860

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

Item

http://www.wikidata.org/entity/Q34691516

description

1987 nî lūn-bûn

@nan

1987 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1987 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1987年の論文

@ja

1987年論文

@yue

1987年論文

@zh-hant

1987年論文

@zh-hk

1987年論文

@zh-mo

1987年論文

@zh-tw

1987年论文

@wuu